REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day REGN SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
10/28/2025
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
8.5%
8/1/2025
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
2.5%
4/29/2025
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
0.2%
2/4/2025
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
4.6%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
3/17 Regeneron Announces Important Advances in Novel COVID-19 Antibody Program 7.4%
11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%
3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%
5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%
4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%
4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%
2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%
11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%
10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%
2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%
Top News Decliners
3/19 Coronavirus Proves Drug Companies To Be Innovators [Forbes] -10.3%
2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%
3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%
5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%
4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%
8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%
5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%
4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%
4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%
3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
REGN
SPY
QQQ
SPX
REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
REGN SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
1/15
11:06 am
regn
Low
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death [Yahoo! Finance]
1/15
06:42 am
regn
Low
Is Regeneron (REGN) Offering Value After Recent Share Price Swings? [Yahoo! Finance]
1/14
07:36 pm
regn
Low
BioNTech (BNTX) Valuation Check As Shares Rebound Despite Longer Term Return Weakness [Yahoo! Finance]
1/14
03:53 am
regn
Low
AbbVie Signs US Deal to Cut Drug Prices, Secure Tariff Exemptions [Yahoo! Finance]
1/13
07:52 pm
regn
Low
Regeneron CEO: AI is as good as the data it can train on [CNBC]
1/13
10:20 am
regn
Low
1 Mooning Stock with Exciting Potential and 2 Facing Headwinds [Yahoo! Finance]
1/11
08:40 pm
regn
Medium
A big Wall Street flip just changed the Regeneron narrative [Yahoo! Finance]
1/10
05:43 am
regn
Medium
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/10
01:07 am
regn
Medium
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at Wall
10/28/2025
06:30 am
regn
8.5%
BEAT
8/1/2025
06:30 am
regn
2.5%
BEAT
4/29/2025
06:30 am
regn
0.2%
BEAT
2/4/2025
06:30 am
regn
4.6%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
1/7
08:02 am
Upgrades
Underperform
Buy
Bank of America Corporation
Medium
4.6%
12/12
12:18 pm
Maintains
Equal-Weight
Equal-Weight
Morgan Stanley
Low
0.5%
12/12
12:18 pm
Maintains
Equal-Weight
Equal-Weight
Morgan Stanley
Low
0.5%
12/10
03:06 pm
Maintains
Equal-Weight
Equal-Weight
Wells Fargo
Low
0.8%
12/10
03:06 pm
Maintains
Equal-Weight
Equal-Weight
Wells Fargo
Low
0.8%
12/4
02:00 pm
Maintains
Buy
Buy
Canaccord Genuity
Low
-0.1%
12/4
09:00 am
Maintains
Outperform
Outperform
BMO Capital
Low
-0.5%
12/4
09:00 am
Maintains
Outperform
Outperform
BMO Capital
Low
-0.5%
12/3
10:27 am
Downgrades
Overweight
Equal-Weight
Morgan Stanley
Low
-1.3%
1/12
06:48 am
regn
Medium
Form 8-K REGENERON PHARMACEUTICAL For: Jan 12
1/8
04:03 pm
regn
Low
Form 4 REGENERON PHARMACEUTICAL For: Jan 07 Filed by: Bassler Bonnie L
1/7
12:03 pm
regn
Low
Form 144 REGENERON PHARMACEUTICAL Filed by: Bassler Bonnie L
1/6
04:21 pm
regn
Medium
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Zoghbi Huda Y
1/6
04:18 pm
regn
Medium
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Thompson Craig B.
1/6
04:16 pm
regn
Medium
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Guarini Kathryn
1/6
04:16 pm
regn
Medium
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: SING GEORGE L
1/6
04:14 pm
regn
Medium
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: Schenkein David P
1/6
04:13 pm
regn
Medium
Form 4 REGENERON PHARMACEUTICAL For: Jan 02 Filed by: GOLDSTEIN JOSEPH L
Show more
Top News Gainers
3/17 Regeneron Announces Important Advances in Novel COVID-19 Antibody Program 7.4%
11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%
3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%
5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%
4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%
4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%
2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%
11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%
10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%
2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%
Top News Decliners
3/19 Coronavirus Proves Drug Companies To Be Innovators [Forbes] -10.3%
2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%
3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%
5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%
4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%
8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%
5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%
4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%
4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%
3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%